JP2014118361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014118361A5 JP2014118361A5 JP2012272828A JP2012272828A JP2014118361A5 JP 2014118361 A5 JP2014118361 A5 JP 2014118361A5 JP 2012272828 A JP2012272828 A JP 2012272828A JP 2012272828 A JP2012272828 A JP 2012272828A JP 2014118361 A5 JP2014118361 A5 JP 2014118361A5
- Authority
- JP
- Japan
- Prior art keywords
- fsp
- vaccination
- tumors
- msi
- endometrium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002255 vaccination Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012272828A JP5890769B2 (ja) | 2012-12-13 | 2012-12-13 | がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ） |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012272828A JP5890769B2 (ja) | 2012-12-13 | 2012-12-13 | がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ） |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015149569A Division JP2016028025A (ja) | 2015-07-29 | 2015-07-29 | がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014118361A JP2014118361A (ja) | 2014-06-30 |
| JP2014118361A5 true JP2014118361A5 (enrdf_load_stackoverflow) | 2015-10-15 |
| JP5890769B2 JP5890769B2 (ja) | 2016-03-22 |
Family
ID=51173521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012272828A Active JP5890769B2 (ja) | 2012-12-13 | 2012-12-13 | がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ） |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5890769B2 (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3065327A1 (en) * | 2017-06-02 | 2018-12-06 | Arizona Board Of Regents On Behalf Of Arizona State University | Universal cancer vaccines and methods of making and using same |
| ES2940087T3 (es) * | 2017-07-12 | 2023-05-03 | Nouscom Ag | Una vacuna universal basada en neoantígenos tumorales compartidos para la prevención y el tratamiento de cánceres con inestabilidad microsatelital (MSI) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| WO2003087162A2 (en) * | 2002-04-18 | 2003-10-23 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
-
2012
- 2012-12-13 JP JP2012272828A patent/JP5890769B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | pH-sensitive nano-systems for drug delivery in cancer therapy | |
| JP2017006120A5 (enrdf_load_stackoverflow) | ||
| CY1118813T1 (el) | Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων | |
| BR112012024590A2 (pt) | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos | |
| IN2015DN00376A (enrdf_load_stackoverflow) | ||
| EA201491299A1 (ru) | Карбаматные соединения, их получение и применение | |
| JP2016528162A5 (enrdf_load_stackoverflow) | ||
| WO2012142529A3 (en) | Clonal strains of attenuated vaccinia viruses and methods of use thereof | |
| MX2012010244A (es) | Composiciones y metodos de tratamiento para enfermedad de parkinson mediante transferencia del gen bndf-flag a traves del poliplex de neurotensina a neuronas dopaminergicas nigrales. | |
| MX2011008430A (es) | Metodos y composiciones para diagnostico y tratamiento del cancer. | |
| BR112012020373A8 (pt) | anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico | |
| TR201909355T4 (tr) | Oral uygulama için proton bağlayıcı polimerler. | |
| JP2016519107A5 (enrdf_load_stackoverflow) | ||
| MX2019011965A (es) | Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso. | |
| WO2020103961A3 (zh) | 一种脑部肿瘤靶向肽及其应用 | |
| RU2016108808A (ru) | Терапевтическое применение vegf-c и ccbe1 | |
| BR112012026224A2 (pt) | métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia | |
| NZ700872A (en) | Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma | |
| JP2016535794A5 (ja) | 急速崩壊性固体剤形 | |
| EP2910634A4 (en) | VACCINE FOR THE PREVENTION OF SWINE DISEASE | |
| JP2014118361A5 (enrdf_load_stackoverflow) | ||
| WO2009067520A3 (en) | Peptides specific for hepatocellular carcinoma cells and applications thereof | |
| JP2015044878A5 (enrdf_load_stackoverflow) | ||
| RU2014101462A (ru) | Раковый антиген | |
| MX357770B (es) | Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer. |